NeuroOne Medical Technologies Corporation announced its participation in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference, scheduled for March 17, 2026. The virtual event will feature company leadership presenting updates on commercialization efforts and pipeline milestones for the OneRF platform, which addresses treatment of brain conditions, pain management, and advanced drug delivery.
President and Chief Executive Officer Dave Rosa and Chief Financial Officer Ron McClurg will represent NeuroOne at the conference, hosting one-on-one meetings with institutional investors. Rosa is scheduled to deliver a company presentation at 1:20 p.m. Eastern Time in Track 1, providing insights into the company's progress and future directions. The presentation will be accessible via webcast at https://wsw.com/webcast/oppenheimer36/nm, while additional conference details can be found at https://www.oppenheimer.com/conferences.
NeuroOne's focus on transforming surgical diagnosis and treatment of neurological disorders positions this conference appearance as significant for stakeholders monitoring medical technology innovations. The company's FDA-cleared product families, including Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System for brain, and OneRF Trigeminal Nerve Ablation System, demonstrate its commitment to minimally invasive solutions that aim to reduce hospitalizations, lower costs, and improve patient outcomes. These technologies combine diagnostic and therapeutic functions, addressing complex neurological challenges.
The implications of NeuroOne's updates at the Oppenheimer conference extend to healthcare providers, investors, and patients. For the medical community, advancements in the OneRF platform could enhance treatment precision for conditions like epilepsy, chronic pain, and other neurological disorders, potentially leading to fewer surgical interventions and better recovery times. Investors may gain clarity on the company's commercialization trajectory and research initiatives, including drug delivery and spinal cord stimulation programs, which could influence market perceptions and investment decisions.
In the broader context, NeuroOne's efforts align with growing demand for innovative neurological care solutions, as neurological disorders affect millions globally and often require costly, invasive treatments. By presenting at a prominent industry conference, the company underscores its role in advancing medical technology that could reshape surgical approaches and patient care standards. The virtual format of the event allows for wider accessibility, enabling a diverse audience to engage with these developments.
As NeuroOne continues to develop its platform, the updates shared at the Oppenheimer conference may signal progress toward more effective and efficient neurological treatments, contributing to improved healthcare outcomes and potential economic benefits through reduced medical costs. This presentation highlights the ongoing evolution of medical technology in addressing critical health challenges, with NeuroOne positioned as a key player in this transformative field.
